Canadian Nuclear Laboratories’ (CNL) Canadian Nuclear Research Initiative-Health Program (CNRI-H) is a program developed by CNL to further the realization of its mission by making its expertise, experience and capabilities available and accessible to the healthcare community to advance new life saving radiopharmaceutical therapies. The focus of the program is Radiopharmaceutical Discovery, Toxicology and Pre-clinical Evaluation research, and the goal of the program is to accelerate the discovery, development and approval of targeted radiopharmaceuticals for the benefit of Canadians while increasing the safety and efficacy of therapies that involve radiopharmaceuticals.